RxDoctor Payments Data

Thomas McFaden, MD

Family Medicine · Birmingham, ALNPI 1821319971

Payments from drug & device makers

$1,171in general payments, 2019–2025

Across 82 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$235
  • Novo Nordisk$167
  • Amgen$120
  • Lilly USA, LLC$115
  • AstraZeneca$112
  • Pfizer$81
  • plus $342 from 14 others

What the payments were for

  • Food & beverage$1,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,171 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$27,037
Medicare patients
39
Services billed
725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$57,038
FarxigaDapagliflozin Propanediol56$47,406
RybelsusSemaglutide35$40,977
JanuviaSitagliptin Phosphate39$36,626
EliquisApixaban21$18,043
MounjaroTirzepatide16$17,391
XareltoRivaroxaban13$10,630
LinzessLinaclotide14$10,046
Tresiba Flextouch U-200Insulin Degludec11$6,910
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$6,736
InvokanaCanagliflozin12$6,721
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$2,950
Atorvastatin Calcium230$2,710
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53$2,582
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$2,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$167$98,01586 claims
AstraZenecaFarxiga, Bevespi Aerosphere$112$54,14271 claims
MerckJanuvia$24$36,62639 claims
PfizerEliquis$81$18,04321 claims
Lilly USA, LLCMounjaro$115$17,39116 claims
AbbVieLinzess$235$10,04614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →